COMMUNIQUÉS West-GlobeNewswire

Elevar Therapeutics Announces First Patients Dosed in Phase 2 Study of Lirafugratinib Among Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
22/06/2026
First patient was dosed at Samsung Medical Center in Seoul, South Korea; a second at Moffitt Cancer Center in Tampa, Florida Global multi-site study includes locations in U.S., Korea, the UK, Spain, and France Study [...]
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
22/06/2026
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced the closing [...]
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
22/06/2026
GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
22/06/2026
Company announcement – No. 27 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, June [...]
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
22/06/2026
-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation - NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: [...]
NADP and AADOM announce partnership
22/06/2026
Joint initiative will address dental office pain points with dental benefits DALLAS, June 22, 2026 (GLOBE NEWSWIRE) -- The American Association of Dental Office Management (AADOM) and the National Association of Dental [...]
Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit
22/06/2026
Cumulative orderbook of over 25 million units secured through wholly owned subsidiary Cana Laboratories across multiple EU and international partners. Multi-year agreements extending up to 10 years provide recurring [...]
Genista Launches Refreshed Brand and Website, Positioning Itself as the Operating System for Product Safety
22/06/2026
The rebrand reflects the company’s evolution from testing laboratory to integrated platform — unifying accredited science, intelligent software, and robotics-enabled automation into one closed loop SAN JOSE, Calif., [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2026
22/06/2026
Aggregated presentation by day and by market Purchases of own shares from June 15th to June 19th 2026 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2026
22/06/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 15 juin au 19 juin 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)
22/06/2026
Company announcement No. 26 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 25, 2026) Copenhagen, Denmark, June 22, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Ozari Health Releases 2026 Online GLP-1 Provider Checklist
22/06/2026
LegitScript-verified New York-based telehealth platform outlines how patients can compare online GLP-1 providers, including Semaglutide starting at $86 per month and Tirzepatide starting at $120 per month. New York, NY [...]
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
22/06/2026
TEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products [...]
Catheter Precision, Inc. Announces Allowance of Key Intellectual Property
22/06/2026
Eight New Patents Issued on Heart Failure Technology Three New Patents Granted on Vascular Closure Technology FORT MILL, S.C., June 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK: NYSE/American), today [...]
GuideAI Health Receives FDA 510(k) Clearance for VascularAssist Occlusion Triage
22/06/2026
AI-Powered Triage Software Helps Radiologists Identify and Prioritize Peripheral Vascular Disease in Lower-Extremity CT Imaging BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (" GuideAI " or the " [...]
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
22/06/2026
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in p47 phox -deficient [...]
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
22/06/2026
Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy REDWOOD [...]
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
22/06/2026
Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6 ‑ month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was generally well-tolerated [...]
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
22/06/2026
The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizures (p=0.015), with [...]

Pages